Voyager Therapeutics, Inc. (VYGR): who owns it and who trades it
As of Nov 16, 2026, VYGR insiders reported 11 open-market sales worth $298K and no purchases in the last 12 months, with 74% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alfred Sandrock (CEO), with $184K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Voyager Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns VYGR
135 funds and institutions reported VYGR shares worth $123M at the end of Q2 2026, about 59% of the company. The largest holder is BlackRock, Inc. with 8.7%.
Funds and institutions (13F) 59%Everyone else 41%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 5.17M | 8.68% | $18.1M | -7% |
| Millennium Management LLC | 4.44M | 7.45% | $15.6M | +30% |
| Armistice Capital, LLC | 3.44M | 5.77% | $12M | -2% |
| Vestal Point Capital, LP | 2.62M | 4.40% | $9.2M | -13% |
| Vanguard Capital Management LLC | 2.35M | 3.94% | $8.2M | +3% |
| Geode Capital Management, LLC | 1.33M | 2.23% | $4.7M | +27% |
| Opaleye Management Inc. | 1.19M | 1.99% | $4.1M | +3% |
| State Street Corp | 1.08M | 1.81% | $3.8M | +14% |
| Two Sigma Investments, LP | 948,517 | 1.59% | $3.3M | +54% |
| Dimensional Fund Advisors LP | 838,184 | 1.41% | $2.9M | -4% |
| Vanguard Portfolio Management LLC | 810,091 | 1.36% | $2.8M | +12% |
| Citadel Advisors LLC | 784,067 | 1.32% | $2.7M | +115% |
| Morgan Stanley | 697,334 | 1.17% | $2.4M | +2% |
| Erste Asset Management GmbH | 638,900 | 1.07% | $2.3M | -42% |
| Renaissance Technologies LLC | 495,236 | 0.83% | $1.7M | -14% |
| Acadian Asset Management LLC | 428,670 | 0.72% | $1.5M | +72% |
| Sphera Funds Management Ltd. | 427,554 | 0.72% | $1.5M | -9% |
| Diadema Partners LP | 413,642 | 0.69% | $1.4M | -2% |
| Northern Trust Corp | 411,803 | 0.69% | $1.4M | +7% |
| AQR Capital Management LLC | 356,109 | 0.60% | $1.2M | +53% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, VYGR insiders reported $0 of open-market purchases and $298K of sales. 74% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | Alfred Sandrock | CEO | Sale plan | 11,511 | $3.87 | $44.5K | Form 4 |
| Feb 24, 2026 | Robin Swartz | COO & CBO | Sale plan | 6,458 | $3.77 | $24.3K | Form 4 |
| Feb 24, 2026 | Alfred Sandrock | CEO | Sale plan | 14,197 | $3.79 | $53.8K | Form 4 |
| Feb 24, 2026 | Nathan D. Jorgensen | CFO | Sale plan | 4,668 | $3.77 | $17.6K | Form 4 |
| Feb 24, 2026 | Todd Alfred Carter | Chief Scientific Officer | Sale plan | 4,174 | $3.76 | $15.7K | Form 4 |
| Feb 18, 2026 | Robin Swartz | COO & CBO | Sale plan | 3,882 | $3.44 | $13.4K | Form 4 |
| Feb 18, 2026 | Todd Alfred Carter | Chief Scientific Officer | Sale plan | 3,301 | $3.44 | $11.4K | Form 4 |
| Feb 18, 2026 | Alfred Sandrock | CEO | Sale plan | 11,732 | $3.41 | $40K | Form 4 |
| Feb 10, 2026 | Robin Swartz | COO & CBO | Sale | 4,569 | $3.85 | $17.6K | Form 4 |
| Feb 10, 2026 | Alfred Sandrock | CEO | Sale | 12,192 | $3.78 | $46.1K | Form 4 |
| Feb 10, 2026 | Todd Alfred Carter | Chief Scientific Officer | Sale | 3,525 | $3.85 | $13.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Alfred Sandrock | President and CEO, Director | – | $184K | Apr 2, 2026 |
| Robin Swartz | COO & CBO | – | $55.3K | Feb 24, 2026 |
| Todd Alfred Carter | Chief Scientific Officer | – | $40.6K | Feb 24, 2026 |
| Nathan D. Jorgensen | Chief Financial Officer | – | $17.6K | Feb 24, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
VYGR short interest
Moderate short interest. 7.0% of VYGR shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 26%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.38M VYGR shares were sold short, 7.0% of the shares outstanding, up 20.3% from the report before. At the average daily volume of 1.07M shares, buying them all back would take about 4.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.38M | 7.03% | +20% | 1.07M | 4.1 |
| Oct 15, 2026 | 3.64M | 5.90% | -8% | 906,539 | 4.0 |
| Sep 30, 2026 | 3.97M | 6.45% | +9% | 618,059 | 6.4 |
| Sep 15, 2026 | 3.66M | 5.93% | -3% | 424,491 | 8.6 |
| Aug 31, 2026 | 3.79M | 6.14% | -4% | 426,555 | 8.9 |
| Aug 14, 2026 | 3.95M | 6.40% | +8% | 447,812 | 8.8 |
| Jul 31, 2026 | 3.64M | 5.91% | -5% | 623,344 | 5.8 |
| Jul 15, 2026 | 3.84M | 6.44% | +7% | 838,985 | 4.6 |
| Jun 30, 2026 | 3.57M | 6.00% | -2% | 698,113 | 5.1 |
| Jun 15, 2026 | 3.65M | 6.12% | -3% | 502,890 | 7.2 |
| May 29, 2026 | 3.74M | 6.28% | +8% | 614,841 | 6.1 |
| May 15, 2026 | 3.47M | 5.82% | -5% | 540,870 | 6.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Voyager Therapeutics company events
Voyager Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026DealCompleted a purchase or sale of a business or assets. Filing
- Oct 21, 2026LeadershipThe Board of Directors of Voyager Therapeutics, Inc. appointed Robin Swartz, the Company’s Chief Business Officer and Chief Operating Officer, to serve as President of the Company, effective immediately. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 13, 2026AnnouncementVoyager Therapeutics, Inc. presented good laboratory practice toxicology data for VY1706, the Company’s investigational tau silencing gene therapy developed to target intracellular and extracellular tau for Alzheimer’s disease, at the Alzheimer’s Association International Conference. Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- Jun 1, 2026AnnouncementVoyager Therapeutics, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for VY1706, the Company’s investigational tau silencing gene therapy developed to target intracellular and extracellular tau for Alzheimer’s disease. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 21, 2026LeadershipNathan Jorgensen, Ph.D. notified Voyager Therapeutics, Inc. of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective May 8, 2026 (the effective time of Dr. Jorgensen’s… Filing
- Mar 9, 2026ResultsReleased financial results. Filing
- Feb 12, 2026LeadershipToby Ferguson, M.D., Ph.D. notified Voyager Therapeutics, Inc. of his decision to resign from his position as Chief Medical Officer of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective February 20, 2026, to pursue a new opportunity. Filing
- Jan 8, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Voyager Therapeutics financials
Famous investors that hold VYGR
4 of the 50 well-known investors we track reported holding VYGR in their latest 13F filing. The largest position is Israel Englander's, worth $13.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 4.88M | $13.1M | 0.0% | +10% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 406,604 | $1.1M | 0.0% | -18% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 323,918 | $868K | 0.0% | -59% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 278,800 | $747K | 0.0% | +18% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named VYGR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G | 6.3% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G | 6.3% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 1.3% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 1.3% |
Questions about Voyager Therapeutics, Inc. (VYGR) stock
Who owns the most VYGR stock?
The largest reported owner of Voyager Therapeutics, Inc. (VYGR) is BlackRock, Inc., with 8.7% of the company. In total, 135 funds and institutions reported holding VYGR at the end of Q2 2026, together about 59% of the shares. See the largest owners.
Are VYGR insiders buying or selling?
In the last 12 months, VYGR insiders reported no open-market purchases and 11 sales worth $298K. The latest trade was on Apr 2, 2026. See every trade.
What is the short interest in VYGR?
As of Oct 30, 2026, 4.38M VYGR shares were sold short, 7.0% of the shares outstanding, up 20.3% from the report before. At the average daily volume of 1.07M shares, buying them all back would take about 4.1 trading days (days to cover). See the history.
Which famous investors hold VYGR?
4 of the 50 well-known investors we track reported VYGR in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $13.1M. See all holders.
Executive pay
Voyager Therapeutics's chief executive was paid a total of $2.5M for the year ended Dec 31, 2025, down 26% from $3.4M the year before. In the last 12 months, Voyager Therapeutics's executives and directors bought no stock on the open market and sold $298K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.